The package includes everything you need, such as the SG2 Metal Spray Gun, RAC IV 515 Switch Tip, 25-foot Duraflex hose, and ...

Hiring in 2026 is slower, more cautious, and more confusing than it has been in years, with employers pulling back on ...

If you have been wondering whether Exact Sciences is still worth buying after its huge run, you are not alone. This breakdown is designed to help you decide if the current price makes sense. The stock ...

At least a handful of Thanksgiving shoppers were disheartened when they went to prepare the holiday staple cranberry sauce last week and found their cans of Ocean Spray did not contain the sauce but ...

Abbott made one of the biggest deals in recent medtech history last week when it announced its plan to acquire Exact Sciences — maker of colon cancer screening test Cologuard — for $23 billion.

Exact agreed to be bought out by Abbott Labs for $105 per share. The buyout is at a hefty premium to the share price at the start of the week, but still well below Exact's 2021 highs. Shareholders ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

In January, Exact Sciences CEO Kevin Conroy told us that 2025 was shaping up to be a transformative year for the diagnostics company. Three cancer test launches, multiple study readouts and one $23 ...

Investing.com -- Exact Sciences (NASDAQ:EXAS) stock soared 17% Thursday, building on Wednesday’s 24% surge after Abbott (NYSE:ABT) announced plans to acquire the cancer diagnostics company in a deal ...

(Reuters) -Abbott will buy cancer test maker Exact Sciences in a deal valued at up to $23 billion, including debt, marking one of its largest purchases in nearly a decade and a bold entry into the ...